<DOC>
	<DOCNO>NCT03083288</DOCNO>
	<brief_summary>Up 30 evaluable participant know suspected breast cancer ( BIRADS 5 image ) undergo FTT PET/CT image primary surgery neoadjuvant therapy . Patients undergo neoadjuvant therapy may choose second FTT PET/CT scan start therapy ( 1 day 3 week ) . FTT PET/CT uptake correlate pathology measure treatment response , subject undergoing neoadjuvant therapy</brief_summary>
	<brief_title>Evaluating Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography ( PET/CT ) Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Participants â‰¥ 18 year age Known suspect ( BIRADS 5 image ) primary breast cancer At least one breast lesion one breast lesion 1 cm great size standard imaging ( e.g . mammography , ultrasound breast MRI ) . Only one type imaging require show lesion 1 cm great order patient eligible participate study . Patients prior diagnosis primary breast cancer opposite breast include . Willing allow use orcollection pathology tissue purpose research either clinical biopsy surgical procedure ( adequate tissue available ) research biopsy Participants must inform investigational nature study willing provide write informed consent participate study accordance institutional federal guideline prior studyspecific procedure . Females pregnant breast feeding time screen eligible study ; urine pregnancy test perform woman childbearing potential screening . Inability tolerate image procedure opinion investigator treat physician Any current medical condition , illness , disorder assess medical record review and/or selfreported consider physician investigator condition could compromise participant safety successful participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>